REVIEW article
Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1626930
This article is part of the Research TopicNext-Generation Technologies for Antibiotic Susceptibility TestingView all 5 articles
Antimicrobial Drug Susceptibility Testing for the Management of Helicobacter pylori Infection in Personalized Eradication Therapy
Provisionally accepted
- 1Lanzhou University Second Hospital, Lanzhou, China
- 2Gansu Second People's Hospital, Lanzhou, China
- 3The First People's Hospital of Jiande City, Hangzhou, China
- 4Gansu Provincial central Hospital, Lanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Helicobacter pylori is a gram-negative bacterium that associated with diseases such as gastritis, peptic ulcer and gastric cancer. In recent years, various treatment options have been evaluated, such as bismuth-containing quadruple therapy, high-dose dual therapy, and the use of acid-suppressing drugs such as Vonoprazan, however, the effectiveness of H. pylori eradication treatment is still dramatically decreasing due to the rising antibiotic resistance rate, and successful eradication of H. pylori has become a major public health problem. Therefore a promising strategy against drug-resistant H. pylori is to individualize treatment based on the outcome of antibiotic resistance. This article reviews the antibiotic resistance situation in recent years in various regions. The advantages and disadvantages of novel antibiotic resistance detection methods are examined, and the therapeutic efficacy of individualized therapy under different detection methods is evaluated. Molecular methods have developed rapidly in recent years, and non-invasive methods can quickly and accurately determine the presence of drug resistance. Clinical application of
Keywords: Helicobacter pylori, antibiotics resistance, Eradication treatment, Culture-based methods, Molecular-based methods
Received: 13 May 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Gou, Ma, Han, Tian, Chen, Xiaojuan and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dekui Zhang, Lanzhou University Second Hospital, Lanzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.